Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Inventory (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Inventory for 3 consecutive years, with $51.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory changed 0.31% to $51.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.7 million, a 0.31% change, with the full-year FY2025 number at $51.7 million, changed 0.31% from a year prior.
  • Inventory was $51.7 million for Q4 2025 at Iovance Biotherapeutics, roughly flat from $51.7 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $65.5 million in Q1 2025 to a low of $9.2 million in Q3 2023.
  • A 3-year average of $35.2 million and a median of $49.8 million in 2025 define the central range for Inventory.
  • Peak YoY movement for Inventory: skyrocketed 396.72% in 2024, then increased 0.31% in 2025.
  • Iovance Biotherapeutics' Inventory stood at $10.4 million in 2023, then soared by 396.72% to $51.5 million in 2024, then increased by 0.31% to $51.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Inventory are $51.7 million (Q4 2025), $51.7 million (Q3 2025), and $49.8 million (Q2 2025).